The Safety and Efficacy of Cangrelor in Endovascular Thrombectomy Compared with Glycoprotein IIb/IIIa Inhibitors

Alex Devarajan,Shouri Gottiparthi,Michael Travis Caton,Aya Ouf,Katty Wu,Daryl T Goldman,Nicole Davis,Nadine Musallam,Jack Y Zhang,Naina Rao,Neha S. Dangayach,Connor Davy,Michael G. Fara,Shahram Majidi,Thomas J Oxley,Christopher Paul Kellner,Tomoyoshi Shigematsu,Reade A De Leacy,J Mocco,Johanna T Fifi,Hazem Shoirah

DOI: https://doi.org/10.1101/2024.06.14.24308962

2024-06-15

Abstract:Background: Cangrelor, an intravenous P2Y12-receptor inhibitor, is a reversible and short-acting antithrombotic medication non-inferior to irreversible Glycoprotein IIb-IIIa inhibitors (GPI) like eptifibatide. However, there is insufficient data to compare the medications in endovascular thrombectomy (EVT) cases requiring emergent platelet inhibition. This study reviews our experience with cangrelor in EVT and compares its safety and efficacy against GPIs. Methods: A large healthcare system retrospective review identified all patients who received cangrelor or eptifibatide intraoperatively during EVT from December 2018 to March 2023 for a cohort study. Clinical data was reviewed. Functional status was defined by the modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) at multiple time points. Binary variables were tested with Pearson ?2 tests or Fisher?s exact tests. Continuous variables were tested with two-tailed t-tests or Wilcoxon tests. Results: Of 1,010 EVT patients, 36 cangrelor and 104 eptifibatide patients were selected. There were no significant differences in baseline functional status or presentations. Cangrelor was most frequently administered for stenting tandem occlusions (n=16, 44.4%) and successful reperfusion occurred in 93.3% of patients (n=30). On multivariate analysis, cangrelor usage was associated with decreased odds of hemorrhagic conversion (adjusted odds ratio (AOR) 0.76, p=0.004) and symptomatic hemorrhage (AOR 0.86, p=0.021). There were no significant differences in thrombotic re-occlusion. Cangrelor was associated with lower 24-hour NIHSS (7.0 vs. 12.0, p=0.013) and discharge NIHSS scores (3.0 vs 9.0, p=0.009). There were no significant differences in in-hospital mortality or length of stay. Cangrelor was associated with improved odds of favorable outcome, defined as mRS 0-2, at discharge (AOR 2.69, p=0.001) and on 90-day follow-up (AOR 2.23, p=0.031). Conclusion: Cangrelor was associated with a decreased risk of hemorrhagic conversion and may lead to favorable functional outcomes for patients during hospitalization when compared to GPIs. Future prospective studies are warranted to investigate its use in EVT.

Neurology

What problem does this paper attempt to address?

This paper explores the safety and efficacy differences between the use of Cangrelor (a reversible, short-acting antiplatelet medication) and the use of Glycoprotein IIb/IIIa inhibitors (such as eptifibatide) in endovascular thrombectomy (EVT). The study retrospectively analyzed data from acute stroke patients who received these two drugs from December 2018 to March 2023.

The study found that Cangrelor had better efficacy in preventing bleeding transformation compared to GPI, and was associated with lower rates of bleeding transformation and symptomatic bleeding risks. Although there was no significant difference in thrombus reocclusion rate, Cangrelor showed lower National Institutes of Health Stroke Scale (NIHSS) scores at 24 hours post-operation and at discharge, indicating improvement in patients' neurological function. Additionally, Cangrelor had a higher probability of achieving a favorable functional outcome (mRS 0-2) at discharge and at 90-day follow-up.

The conclusion of the paper suggests that Cangrelor may be a safer and more effective antiplatelet option in emergency stroke situations, but further prospective research is needed to validate its application in EVT.